

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026


To the CEO
Regeneron
Pharmaceuticals INC
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
USA

Regeneron Pharmaceuticals INC TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Regeneron Pharmaceuticals INC has been TOP Rated at rank 22 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Regeneron Pharmaceuticals INC. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Regeneron Pharmaceuticals INC (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Regeneron Pharmaceuticals INC
Amount	USD 9,900
Order no.	2026-0000872589

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Regeneron Pharmaceuticals INC

Date, location, name



The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Regeneron Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 10.0% points.

The company's Economic Capital Ratio, given in the ranking table, is 363%, being 134% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	18,021,900
Cost of Goods Sold	0
Intangible Assets	1,257,400
Liabilities, Current	4,368,400
Liabilities, Non-Current	4,213,400
Other Assets	21,279,400
Other Compr. Net Income	85,400
Other Expenses	2,940,600
Other Liabilities	720,000
Other Net Income	1,652,800
Other Revenues	14,342,900
Property and Equipment	0
Research and Development	5,850,200
Selling, General and Administrative Expense	2,700,000

Output Variable	Value in 1000 USD
Assets	40,558,700
Liabilities	9,301,800
Expenses	11,490,800
Revenues	14,342,900
Stockholders Equity	31,256,900
Net Income	4,504,900
Comprehensive Net Income	4,547,600
BaseVar	38,716,200
ECR before LimitedLiability	292%
Economic Capital Ratio	363%